The COVID-19 epidemic caused by the SARS-CoV-2 virus has reached pandemic proportions and caused worldwide instability. With limited ICU beds and insufficient respiratory support, healthcare systems were unprepared to treat patients who progressed to a severe acute respiratory syndrome, the dire form of the COVID-19 disease. The scientific community is still learning about viral mechanisms, infection, and immune response time-courses, especially in highrisk subpopulations with pre-existing health conditions where the infection has demonstrated a higher likelihood to degenerate into a critical condition (e.g., elderly 1 ). An effective and safe vaccine has the theoretical potential to rectify an epidemic. At present, there is no approved vaccine against SARS-CoV-2. While there are more than 100 COVID-19 vaccine projects in various stages of development, it will take time to validate a quality product that is effective, safe, and scalable. Even though the preliminary data on some vaccine candidates seem promising in providing a high level of protection, their durability and long-term safety remain to be evaluated over time. The findings of these early studies will probably result in improvements and identification of required epitopes and antigens that will elicit a protective immune response. This will necessarily further extend development times. Thus, it is critical to find a set of effective pharmacological strategies that can prevent viral infection, curb transmissibility, and lower the risk for disease progression. This manuscript discusses therapeutic strategies from two perspectives:
(I) Agents intended to inhibit viral replication (antiviral strategy); (II) Agents intended to modulate host immune/inflammatory overreactions (immunoregulatory strategy). These two approaches may be deployed in sequence or over the course of a viral infection and disease development.
First, the antiviral strategy is intended to lower the risk of disease progression and severity, which may lead to death. Second, if the antiviral time window (early phase) is missed, an J o u r n a l P r e -p r o o f immunoregulatory strategy may be considered to reduce the deleterious effects of a hyperimmune response (later phase).
Current antiviral drug candidates tested or approved for COVID-19 are compounds that have been repositioned from other indications. Generally, drugs can be repositioned for the treatment of the SARS-CoV-2 infection if they have evidence of in vitro inhibition against human coronaviruses (CoV). For example, remdesivir, which was originally intended for treating Ebola, has been recently approved for the treatment of COVID-19 requiring hospitalization; the anti-malaria drug chloroquine is also being evaluated for COVID-19 treatment; the anti-HIV drug combination lopinavir-ritonavir is used off-label in many lower-income countries against COVID-19. Antivirals, however, may fall short in severely ill COVID-19 patients. At later stages of viral infection or when subjects exhibit severe COVID-19 symptoms, immunoregulatory agents such as dexamethasone may be a more appropriate agent to ameliorate severe and critical conditions. As of today, there are more than three thousand clinical trials registered in clinicaltrials.gov with more than 30 FDAapproved drugs repositioned for COVID-19 alone or in combination with/without supportive care (e.g., oxygen therapy). Although many questions remain, a unified and integrated pharmacological strategy against COVID-19 may enable informed decisions on prioritizing the optimal use of clinical testing and global resources.
Questions regarding therapeutic windows, regimens, and effectiveness in drug repositioning, as well as the dissemination and cost-effectiveness of therapy, are issues that, in times of pandemic, call for readiness and low cost. Systems Pharmacology is a novel interdisciplinary concept envisioned by stakeholders interested in integrating real-world data produced in the laboratory and the marketplace into a novel quantitative tool. This is based on computer modeling and simulation, plus the use of artificial intelligence, where possible, with the scope to de-risk drug development and clinical pharmacology 2 . Systems Pharmacology has the J o u r n a l P r e -p r o o f potential to combine evolving COVID-19 knowledge by relating pathology, viral load time-course, and pharmacological strategy into an optimized therapeutic and drug development methodology.
For instance, remdesivir pediatric dose included in the label (hospitalized weighing 3.5-40kg, or <12 of age weighing >3.5 kg) was inferred from adults by the use of the computational physiologically based pharmacokinetic modeling (PBPK) 3 . In order to apply Systems Pharmacology to rapidly repositioning and deploying new strategies against COVID-19, we need collective and quantitative knowledge of the infection, the disease, and the pharmacological landscape. In this text, we start with a general quantitative overview of SARS-CoV-2, COVID-19, mechanisms of infection, viral load dynamics, and pharmacology, all together to form a timeline of infection with the scope of timing the best intervention. We then introduce opportunities and applications for Quantitative Systems Pharmacology (QSP) for designing COVID-19 therapies, such as the deployment of physiologically-based pharmacokinetic modeling (PBPK) for drug repurposing. We conclude the article proposing proof-of-concept technology, particularly, introducing in the COVID-19 landscape, the idea of transforming short-acting antivirals into long-lasting drugs for the COVID-19 long-acting therapy. Modeling utilization will reveal valuable information for drug development and clinical pharmacology with the potential to change the course of current and future pandemics. SARS-CoV-2 is a novel single-stranded RNA beta-coronavirus. SARS-CoV-2 presents epidemiologically with low traceability and a high reproductive number, R 0 . Thus far, collating the available reports for R 0, we estimate R 0 to be in the range of 2. 8-5.7 . For comparison, R 0 is 1.5 for influenza H1N1 and 11 for highly transmissible varicella-zoster 6, 7 . The fatality rate for SARS-CoV-2 infection varies from 7.2% in Italy to 0.7% in South Korea with the latter being a more accurate representation of the SARS-CoV-2's fatality rate as South Korea has carried out more extensive population-wide viral screenings 4 . Additionally, fatality rates may be inflated due to confounding factors from preexisting co-morbidities or co-infections such as cardiovascular disease, diabetes, chronic respiratory disease, and cancer [8] [9] [10] .
Mild symptoms should appear around 5 days after the putative event of infection. These symptoms include fever (80%), chills (15%), sputum (32%), cough (55%), rhinorrhea (19%), sore throat (23%), malaise (18%), myalgia (18%), and diarrhea (18%) 11 . Hence, COVID-19 can initially present with symptoms similar to that of seasonal influenza. So, in some people, COVID-19 resolves via the standard of care for influenza. However, in a fraction of symptomatic patients (especially in subpopulations at risk), mild symptoms can deteriorate into severe clinical signs typical of a severe respiratory syndrome, which could lead to death by lung or another organ failure. A thorough report from the Chinese Center for Disease Control and Prevention shows that among 44,672 patients with COVID-19, 81% of cases were classified as "mild" 11 . Of the milddisplaying symptoms, 19% progressed to more severe symptoms (14% as severe; 5% as critical), while 81% recovered with standard care 11 . There is a blurred line between "severe" and "critical" patients: in general, severe individuals display clear pneumonia symptoms that might or might not J o u r n a l P r e -p r o o f require respiratory support; critically ill patients need to be admitted to intensive care units (ICU) in the hospital and put on respiratory aid (e.g., physical positioning, oxygen supplementation or positive-pressure ventilation) to provide sufficient oxygenation to sustain life. Among critically ill patients, 49% might die 11 .
Based on current virology, viral host interactions, and the time-course of disease development, we have provided an integrated physiological, cellular, and intracellular schematic of proposed mechanisms leading to disease development and host immune response. The SARS-CoV-2 virus's most likely entry point is through exposure to aerosolized viral particles in the air that subsequently infect the human airway's epithelium ( Figure 1A ). SARS-CoV-2 features a long genetic sequence located on a positive-sense strand coupled with nuclear proteins N. The genetic material is enclosed in a typical coronavirus structure made of spike proteins S, membrane proteins M, and envelope proteins E ( Figure 1A ). Viral particles gain access to the cells lining the respiratory epithelium and the infected cells generate new viruses that can spread through cell-to-cell or cell-free interactions. As a response, the host infected cell flags the infection to the immune system upon lysis or shedding of the virus to nearby cells and resident monocytes ( Figure 1B) . The resident monocytes, as well as the epithelium cells, release inflammatory factors or signals as cytokine and chemokines, which recruit blood and lymph node mononuclear cells and trigger other pro-inflammatory mechanisms.
In some individuals, dysregulated signaling could set off the so-called "cytokine storm", the most dangerous consequence associated with COVID-19 disease progression (for more on the cytokine storm, see II.D).
While the body arranges for self-defense, viral replication carries on in the lung cell cytoplasm ( Figure 1C ). These lung epithelial cells, especially those in lung alveoli (air sacs), are J o u r n a l P r e -p r o o f critical to the exchange of CO 2 /O 2 in the blood. This is why a significant fraction of infected patients may experience large drops in blood oxygen levels. Once cells become infected or lysed, they are no longer able to oxygenate the blood. At the cellular level, the viral infection should commence with the attachment of viral spikes to the host cell receptors ACE2, primed by TMPRSS2. While the exact multimeric structure and conformation change requirement in host receptors for viral entry is under debate, once inside, the invading virus releases genetic material and accessory proteins into the host cytoplasm. SARS-CoV-2's RNA functions as an mRNA directing the synthesis of polyproteins and two proteases (M pro and PL pro ). Proteases play an essential role in cutting polyproteins into functional pieces, i.e. the structural proteins (M, S, E, N, Figure 1A efficiency, as the latter is a more destructive mechanism. The progeny released are ready to infect other cells repeating the abovementioned cycle at an exponential pace.
In severe conditions, patients require oxygenation support to lower the risk of respiratory failure. Other failures can occur in distant organs, such as the heart, brain, GI, and kidney. Any of these failures can be fatal ( Figure 1D , see later the hypothesized mechanisms causing organ failure during a cytokine storm, II.D).
SARS-CoV-2 is a pathogen that is sensed by the innate immune system in humans.
Although the SARS-CoV-2 immune response is still elusive, we rely on the joint understanding of J o u r n a l P r e -p r o o f current and past epidemic causing CoVs (e.g., 2003 SARS-CoV-1 and 2012 MERS-CoV). Viral RNA is believed to be recognized by pattern recognition receptors (PRR) in humans. Upon PRR activation, downstream signaling cascades trigger the secretion of cytokines. Another mechanism for immune/inflammatory activation could involve the release of destructive enzymes from lysed cell's lysosomes. Among cytokines, type I/III interferons (IFN) are considered the most important for antiviral defense, but other cytokines, such as interleukins (IL-1 or IL-6), are also released in response to CoV viral infection. In concert, IL and IFN may induce antiviral activities to clear virally infected cells, and later on, potentiate the adaptive immune response. However, CoVs have developed mechanisms to evade innate responses 13 .
Among SARS-CoV-2 evading markers, patients with severe COVID-19 demonstrate remarkably impaired type I IFN (IFN-alfa and IFN-beta) signatures as compared to mild or moderate cases, hence suggesting viral inhibition of IFN induction and signaling 14 . It is likely that to prevent the downstream signaling of IFN release, CoV proteins inhibit the steps bridging the receptor IFNAR2 and transcription STAT1 (JAK pathway) resulting in poor type I IFN production.
Furthermore, viral NSP9 and NSP10 could induce, among others, IL-6 over-production, potentially by inhibiting the NKRF gene (an endogenous NF-kB repressor) 13 . Collectively, cytokines from infected lung cells and those released from monocytes elicit inflammatory pathways in resident and circulating monocytes. In some patients, the dysregulation of these proinflammatory processes by the SARS-CoV-2 infection leads to a cytokine disease, also known as a "storm".
A cytokine storm causes lung hyper-inflammation and non-specific attacks to the host, which could lead to tissue damage, like those observed in COVID-19 patients' lungs. Lung tissue damage engenders particulate matter in the bloodstream (dead cells plus immune precipitate), which may lead to the formation of thrombi or blood clots. These blood clots may be the cause of distant organ failures, such as brain infarction and heart attacks. Other organs could also fail, such J o u r n a l P r e -p r o o f as the kidney, liver, and gastrointestinal tract. This hypothesis is consistent with the finding that alveolar-capillary microthrombi incidence is 9 times more prevalent in COVID-19 patients compared to those with influenza 15 .
Based on current knowledge, as presented above, about the virus and host immune response, we provide a quantitative link between the symptoms, pathology, infection mechanisms, and pharmacological actions starting from the time of infection. We have extracted information from COVID-19 viral dynamics, host response, and disease progression, which are graphically summarized in Figure 2 . The timeline schematic in Figure 2 is an integrated understanding based on peer-reviewed publications and verified COVID-19 consortia databases employing text analytics and network meta-analysis (implemented by AI groups through opensource web tools) [16] [17] [18] . However, it should be noted that correlation analysis of the viral load with disease progression is still limited by data quality, which is thwarted by several factors, such as the sampling site, timing, and assay precision of the test.
As shown in Figure 2 , it is likely that, soon after infection, viral load increases rapidly starting from day 2 in the upper respiratory tract. It has been shown that ACE2 is expressed with higher cell density in the upper respiratory tract which highlighted the nasal susceptibility to SARS-CoV-2 with likely subsequent aspiration-mediated virus seeding to the lung in SARS-CoV-2 pathogenesis 19 . This would seem to signify a higher probability of initial infection in the upper airways. This is why viruses found in the nasal mucosal droplets are the likely source of transmission to people in close contact. It is unclear if the lower respiratory tract follows suit or has a delay. It is also unclear what the intensity of the viral load is in the lower tract. Recent findings in patients with critical conditions suggest that lower tract delay is minimal while the magnitude is much higher than in the nasal tract or throat. Furthermore, the lower tract viral load J o u r n a l P r e -p r o o f seems to linger much longer, even if the upper tract samples are tested negative in the same individuals 20 . Regardless, symptom onset is expected around day 5 from infection. The viral load in the upper tract should peak around day 10 from infection [21] [22] [23] [24] . Therefore, with the viral load depicted in Figure 2 , pre-symptomatic subjects can transmit the virus for 2-4 days before testing.
Another problem in this pandemic is that asymptomatic individuals (i.e., not exhibiting symptoms)
can still transmit the virus as long as their viral load is high enough. According to epidemiological modeling, 43% of exposed individuals to SARS-CoV-2 infection remain asymptomatic, further hindering traceability and intervention capacity 16 .
The turning point of the disease may begin around day 15 from infection, where symptoms either begin to resolve or further deteriorate into severe respiratory conditions. Seroconversion (antibodies against SARS-CoV-2) in uncomplicated patients may start soon after the viral load peak 25 ; however, antibody appearance in the blood is generally observed around day 21 26 . Initially, SARS-CoV-2 specific antibodies are detected as an IgM class of antibody (10 binding sites); then IgG class molecules appear (2 binding sites). Both IgM and IgG antibodies against SARS-CoV-2 plateau around day 28 from the infection event (that is 3 weeks from symptom onset) 26 . Whether seroconversion is correlated with the lowering of the viral load or the improvement of symptoms, it is still unclear.
Depending on the host's preexisting conditions and immune response capabilities, immune response and standard care (including oxygen therapy) might not suffice to fight the infection. In these individuals, COVID-19 progresses to severity at later phases of the infection time-course. In this situation, the viral load may persist at very high levels with a subsequent massive host-cell lysis that could trigger the cytokine storm. In severe and critical patients, viral dynamics is still elusive, but shreds of evidence indicate a persisting respiratory viral load and an undeveloped and/or delayed antibody response 20,26,27 . J o u r n a l P r e -p r o o f Viral antigen-specific immune response unpredictability, together with an apparent slowerthan-anticipated antibody induction, provides a strong rationale to rely on pharmacological intervention. According to the viral load dynamics and time-course, an antiviral strategy should be deployed at early symptom onset (ideally before the peak), especially in individuals who are exposed or at a high chance of exposure. An antiviral strategy, either as prevention or treatment, at an early phase, might flatten the viral load, thus reducing the risks associated with the COVID-19 disease progression. If the antiviral window is missed, then antiviral usage would likely be less effective in the case of sustained peak levels. In this situation, the disease evolves to a point where it mounts a disproportionately strong innate immune response (viz., cytokine storm). Therefore, immunomodulatory drugs should be used to quench the cytokine storm to avoid tissue damage and multiple organ failure. Having formed an introductory body of knowledge about the virus and disease and having positioned each class of pharmacological intervention (antiviral vs. immunomodulatory) in the appropriate timeframe, we will next discuss each pharmacological class and its most important available candidates, at present.
Antiviral drugs are compounds intended to disturb the viral cycle (see II.C). The intent is to reduce the magnitude of the SARS-CoV-2 load, and, perhaps, to completely suppress viral replication, allowing the development of protective immunity against the virus. Currently, there are no compounds designed as an anti-SARS-CoV-2 drug, nor is there is sufficient time to design one with proven safety and preliminary efficacy. Therefore, compounds intended for other indications, with demonstrated potential for SARS-CoV-2, are being repositioned to COVID-19.
Drug repositioning can be a much more efficient entry into clinical studies. Drugs in advanced studies or that are already approved not only have general safety information available, but their J o u r n a l P r e -p r o o f manufacturing processes are well-defined. In the following, we categorize antivirals based upon their putative pharmacologic actions and checkpoints in the viral replication lifecycle.
The first step in infecting human host cells involves binding to the cell's Angiotensinconverting enzyme-2 (ACE2) with the SARS-CoV-2's spike protein S in the trimeric conformation.
As successful contact with the cell is essential to gain entry into host cells, the interfering agent blocking this step represents an intervention point to abort infection altogether. There are clinically approved drugs that inhibit ACE2 to treat hypertension called ACE-inhibitors (ACEi) and angiotensin-receptor blockers (ARB). Thus, it is thought that ACEi and ARB may compete with virus spike protein to inhibit viral entry and the subsequent infection of human lung cells. However, spike viral proteins appeared to upregulate ACE2 expression in animal lung cells and thus raised concerns about whether receptor overexpression induced by ARBs and ACEi could enhance viral entry 28 . On the other hand, controlling blood pressure can be useful against cytokine storm effects. A list of ongoing ACEi and ARBi under clinical investigation for COVID-19 is listed in Table 1 .
Other compounds that are thought to inhibit viral entry, such as chloroquine derivatives, nelfinavir, or monoclonal antibodies, are also discussed later.
The main SARS-CoV-2 protease (M pro ) is considered a promising drug target, as its properties are unique and distinct from human proteases. Scientists believe that inhibition of SARS-CoV-2 proteases is key to reducing viral replication and viral load 29 . The sequence and structure of this protease have been reported to be similar to that of other CoV, and therefore facilitates the search for inhibitors and compounds for this drug target through repositioning from existing compound libraries. The inhibitor of HIV protease, lopinavir, was found to inhibit SARS-J o u r n a l P r e -p r o o f CoV-2 protease and viral replication at a therapeutically meaningful range. Lopinavir affinity for CoV's M pro was computationally confirmed in several docking assessments 30, 31 . Lopinavir (in combination with ritonavir) was thus deployed immediately around the world for preventing SARS-CoV-2 infection and disease progression 32 .
An early study result for lopinavir-ritonavir on hospitalized COVID-19 (moderate-severe) patients indicates that lopinavir-ritonavir appeared to have no clear impact in reducing the duration of patients in ICU or need for mechanical ventilation 33 . However, in a more recent randomized study enrolling patients at early symptom onset in Hong Kong (n = 127, recruited within 7 days from symptom early onset), the effects on early treatment with lopinavir-ritonavir may have shown survival benefits. In this study, the investigators compare lopinavir-ritonavir vs.
lopinavir-ritonavir plus ribavirin (a broad-spectrum antiviral) and IFN-beta 34 . When lopinavirritonavir was given either alone or in combination with ribavirin and IFN-beta, no patients died in either treatment group, while no difference in adverse effects outcomes was observed between groups 34 . The addition of ribavirin and IFN-beta to lopinavir-ritonavir did not deliver a significant impact but provided general symptoms relief and more rapid recovery time. Therefore, the role of lopinavir-ritonavir for COVID-19 patients with mild or moderate symptoms in the early course of viral infection could be beneficial. But ongoing clinical studies may shed light on how and when this therapy should be used to provide optimal effects with safety. In waiting for conclusive results about lopinavir-ritonavir, its usage is thus considered off-label, because to date lopinavir-ritonavir is not approved by the U.S. FDA as a treatment for COVID-19.
Other HIV protease inhibitors, including darunavir and nelfinavir, are also being examined.
In a small RTC of 30 subjects, darunavir was reported as not promising in resolving the disease in patients admitted with moderate symptoms after 5 days of treatment vs. standard of care 35 .
Nelfinavir exhibited very high potency in vitro against SARS-CoV-2 36 . It has been hypothesized that J o u r n a l P r e -p r o o f nelfinavir acts not only to inhibit protease but also to inhibit cell fusion by the spike 37 . Nelfinavir is awaiting clinical setup, so as of now, we can only express interest in its potential (see Section V and Table 2 for additional details about nelfinavir pharmacokinetics). Overall, while more potent and SARS-CoV-2 protease-specific inhibitors are being sought, repositioning HIV protease inhibitors, particularly the combination lopinavir-ritonavir may be the best option available for inhibiting SARS-CoV-2's protease activity. Ongoing clinical studies should provide clarity about a regimen that can achieve an optimal therapeutic response, while modeling can guide the choice (See Section V and Table 2 ).
Inhibiting the SARS-CoV-2 RNA-dependent RNA-Polymerase (RdRP) enzyme is also a potential strategy to stop viral replication. Drugs that inhibit the HIV reverse transcriptase step have been proven to lower viral loads and enable HIV patients to live a quality life; in this way, HIV has changed from a deadly to a manageable chronic disease 38 . Among the RdRP inhibitors tested, remdesivir exhibits a high potency (nanomolar range) against MERS-CoV as well as SARS-CoV-2 in vitro and in animals 39 . Due to the recent containment of the Ebola outbreak, there is a large stock of remdesivir and a good manufacturing process. Following an initial use under emergency use authorization (EUA) for treating patients with severe COVID-19 disease, it has gained on October 22, 2020, the FDA approval for adults and pediatric patients (hospitalized weighing 3.5-40kg, or <12 of age weighing >3.5 kg) for the treatment of COVID-19 requiring hospitalization. Remdesivir should only be administered intravenously (IV) in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. In a randomized controlled clinical trial study (n = 237), where patients with severe COVID-19 were treated concomitantly with lopinavirritonavir, interferons, and corticosteroids, the time to clinical improvement was evaluated. The remdesivir arm was not associated with a difference in time to clinical improvement (although a J o u r n a l P r e -p r o o f trend in clinical improvement in those treated earlier was observed) 40 . While waiting for the final report for a larger study, another interim report indicates that the use of remdesivir provides a significant reduction in time to recovery for patients on ventilators compared to those in saline control by 2-3 days 41 .
Another antiviral drug ribavirin can serve as an RdRP inhibitor. It is indicated for chronic hepatitis C and it is used in several viral infections of the respiratory system (e.g., RSV). Although characterized by a low in vitro potency against SARS-CoV-2 42 , as previously mentioned, it is a confounding factor in a combination study that improved clinical recovery time in non-critical patients. Nonetheless, it does not seem likely that ribavirin can meaningfully impact COVID-19 treatment 34 .
Several agents that may influence multiple pharmacological and immunological pathways in viral infection and host responses are being tested. These agents include inhaling therapies with and without steroids to improve ventilation in COVID-19 patients, or non-specific supplements, such as vitamin D, C, or stem cells, for a total of 30% of the global clinical trial effort (summarized in Figure 3 ). We will not include them in our discussion, as the pharmacological basis for these agents is not yet fully characterized. Thus, only selected agents are discussed below.
Originally discovered and used as an anti-malarial agent, chloroquine (CQ) and its hydroxyl derivative hydroxychloroquine (HCQ) have been used as immune-modulatory agents to treat autoimmune conditions such as psoriasis, arthritis, and lupus. Thus, their immunomodulatory functions have been clinically validated and prescribed world-wide by rheumatologists. The information available to date suggests that CQ and HCQ inhibitory responses in viral replication J o u r n a l P r e -p r o o f involve multiple mechanisms at the cellular and systems levels: (I) inhibiting entry by preventing the glycosylation of ACE2 cell surface receptors (entry blocker); (II) inhibiting acidification of the endosome to prevent viral RNA release; (III) augmenting antigen processing for MHC class I and II presentations to enhance immune response; (IV) enhancing the activity of regulatory T cells.
Because of HCQ's putative multiple effects against the virus and cytokine storms, plus worldwide availability at low cost, it was approved under emergency use authorization (EUA). However, preliminary results reported recently from an unblinded RCT in patients with COVID-19 (mildcritical) admitted to 176 centers in the UK did not yield positive outcomes. In this report, 418 were given HCQ and 788 were allocated to standard care. The 28-day study found that HCQ did not reduce mortality but increased the length of hospital stay and increased the risk of progressing to invasive mechanical ventilation or death 43 . Because of these negative outcomes on safety and a potential increase in hospital stay 43 , along with other similar discouraging results 44, 45 , as well as safety concerns on QT-elongation at elevated doses, the FDA revoked the EUA of CQ and HCQ as a COVID-19 treatment on June 15, 2020. We are still waiting for a conclusive decision about when and who should benefit from HCQ as its low cost and high accessibility still represent an attractive option.
Because biologics based upon recombinant antibody production at the pharmaceutical scale may take some time to develop, scientists have been testing the century-old idea of using antibodies in serum collected from those who fully recovered. This passive immunotherapy is being tested via RTC studies. In an interim report of 81 subjects, 38 received convalescent plasma (CP) and the remainder received standard care. It showed that mortality and progression to respiratory aid rates were zeroed with CP vs. 9% and 14%, respectively, of those under the standard of care 46 
In this paper, we divide the pharmacological strategies into two classes: antiviral and immunomodulatory. Currently, all clinical studies intended for COVID-19 are registered online on ClinicalTrials.gov. Based on the total clinical trials, 45% and 25% entail the usage of a compound as an antiviral or immunomodulator, respectively ( Figure 3 ). Of the antivirals, we mention herein 74% of the registered trials. Therefore, the discussed antivirals cover a large spectrum of leads for COVID-19. Ideally, antiviral therapy should be considered before symptoms or at mild/moderate symptom onset, up to the viral peak at day 10 (see Figure 2 ). Apart from some positive signals for remdesivir, monotherapy has been shown to provide limited efficacy in clinical studies, especially in moderate-severe patients. From HIV experience, ideally, combinations of antivirals acting upon different viral cycle points may lead to better performances. To reduce the duration of viral J o u r n a l P r e -p r o o f shedding (correlating with transmissibility) and the risk of viral rebound (generally linked to the virus becoming drug-resistant), an optimal treatment would likely include a combination of drugs targeted to multiple viral proteins, such as a protease inhibitor, e.g., lopinavir (plus ritonavir), and a polymerase inhibitor, e.g., remdesivir. Furthermore, interventions like monoclonal antibodies against SARS-CoV-2 aiming to block entry or kill virions could rapidly reduce viral load and thus serve as useful additions to the antiviral armamentarium.
As mentioned above, disease development and progression after SARS-CoV-2 infection include a later stage of tissue damage due to systemic infections beyond lung cells (Figure 1d and 2). As a result, overstimulated host native (and mostly non-SARS-CoV-2 specific) immune results lead to cytokine storm syndrome. In these patients, impaired SARS-CoV-2 clearance, lower levels of interferons (which are generally involved in interfering with the success of virus infection to host cells), increased neutrophil extracellular traps, increased pyroptosis, and other unknown mechanisms are biomarkers reported to be associated with severe disease courses in patients experiencing a cytokine storm 13 . Once a cytokine storm occurs, anti-viral treatments alone may not be sufficient to reduce the time-to-recovery endpoint or even reverse the course allowing the patient to recover. Thus, antiviral therapy may be combined with appropriate immunomodulatory agents to counteract the massive load of cytokines in the body. We will discuss in the following section cytokine-directed therapies intended to remedy dysregulated inflammatory signaling pathways.
Corticosteroids are well-tested immunosuppressive and anti-inflammatory agents that can potentially function as anti-cytokine storm agents. Corticosteroids bind to the glucocorticoid 
Interferon-beta-1a (IFN-beta), in contrast to IFN-alfa (which is more associated with antiviral effects), has been demonstrated to down-regulate inflammatory responses leading to cytoprotecting on oligodendroglia in multiple sclerosis patients 53 . By reducing vascular leakage, IFN-beta modulates cytokine/monocyte trafficking. IFN-beta may also have an antiviral effect: IFNbeta induces the interferon-stimulated genes in the nuclei that should slow down viral replication 13 . It is thought that IFN-beta could reduce the clinical impact of cytokine storms. Recently, IFNbeta was used in combination with lopinavir-ritonavir plus ribavirin to lower the recovery time for mild-moderate COVID-19 patients 34 . In a recent study, the effects of IFN-beta alone vs. standard of care were evaluated in COVID-19 patients enrolled in the hospital. The results indicate that IFNbeta significantly decreased 28-day mortality (especially if given early), as well as significantly increased the recovery rate (average recovery was 14 days from admission) 54 . Interestingly, when antiviral IFN-alfa-2b plus ribavirin was compared to lopinavir-ritonavir, investigators reported no J o u r n a l P r e -p r o o f significant difference between groups in mild-moderate individuals, seemingly downgrading the role of IFN-alfa for COVID-19 55 .
Cytokines, originally discovered as cell-to-cell communicating factors found within the tissues and cells, are nearly undetectable in plasma. However, accumulated clinical data suggest that disproportionate and elevated pro-inflammatory cytokine and interleukin levels are found in plasma (viz., cytokine storm), which correlates with severe respiratory failure in COVID-19 13 . Proinflammatory interleukins are IL-1, 2, 6, 8, 10, 18, and 33 13 . Among ILs, the most critical is thought to be IL-6, which is typically associated with an inflammatory state. Tocilizumab (H-LaRoche, CH) is an IL-6R-specific monoclonal antibody that inhibits IL-6 function and is approved for rheumatoid and juvenile rheumatoid arthritis, Crohn's, and Castleman's diseases. Numerous observational SARS-CoV-2 studies point to a general clinical improvement due to a marked decline of proinflammatory markers in critically ill patients by tocilizumab administrations [56] [57] [58] . In a recent small RTC study (n = 65, 33 in tocilizumab vs. 32 control), however, tocilizumab did not increase the cure rate but it did improve oxygenation in patients experiencing bilateral pulmonary lesions 59 . Agents intended to block another inflammatory interleukin response called anakinra (an IL-1 receptorlinked to IgG Fc domain), are being tested. Inhibition of JAK pathways (see Section II.D) is also under clinical evaluation via the use of baricitinib and ruxolitinib: the former is repositioned from rheumatoid arthritis; the latter, is repositioned from high-risk myelofibrosis. Note that baricitinib, in combination with remdesivir, has just gained EUA for the treatment in hospitalized patients requiring respiratory support. It is reported in Table 1 a list of IL-blockers.
In our discussion, we have included 47% of the interventional immunoregulatory agents intended (FDA-approved and repositioned) for COVID-19 ( Figure 3) . Based on the time-progression from infection to disease development (Figure 2) , pharmacological or biological agents intended to modulate host (non-viral specific) immune responses may perform best at later stages of the disease, especially when a cytokine disease is diagnosed. The over-production of IL-1 and IL-6 could lead to a range of untoward systemic effects that should be counteracted by IL-blockers to provide general relief and better oxygenation (e.g. tocilizumab or baricitinib). Currently, dexamethasone is the only medication with a demonstrated reduced death rate based upon RTC studies in patients in critical condition (requiring breathing support). Nonetheless, in the early stages, the emerging evidence seems to point to a positive outcome when using IFN-beta (both as antiviral and immunomodulator) with/without antivirals.
Traditional Chinese medicine (TCM) has a history of over 3,000 years and an accumulated clinical practice in handling past viral epidemics. TCM involves the use of inexpensive herbs that could have both antiviral and immunomodulatory effects. Some authors believe that TCM focuses on improving blood circulation, while others believe that TCM exerts pharmacological effects.
During the SARS-CoV-1 crisis in China, TCM played an important role in complementing disease management with Western approaches to clinical care. TCM use has been reported to correlate with positive clinical effects, such as better control of fever and lesser usage of steroids 60 .
Although drug interactions with traditional Chinese medicines may occur through the main pathway of cytochrome P450 enzymes, it is reported that 92% of Chinese COVID-19 patients have received supplements from TCM without increasing adverse drug reactions to Western medicine regimens 61 . In Table 1 we report TCM candidates included in clinical trials as supportive medicines. For example, Lianhua Qingwen is a medicine composed of 13 herbs that are commonly J o u r n a l P r e -p r o o f used to treat seasonal influenza with an in vitro potential for other pathogenetic CoV 62 .
Integrating Western and TCM for COVID-19 disease management may improve both hospitalized and home patient's quality of life.
The quantitative aspect of the Systems Pharmacology is also known as Quantitative Systems Pharmacology or QSP. QSP is a set of modeling and simulation tools that integrates biological pathways, cells, and organs up to simulating the whole body (e.g., PBPK). QSP and PBPK were initially used as computational methods to fill the knowledge gap and improve the translation of drugs in vivo and in humans. Currently, they are applied to de-risk drug discovery and drug development research by integrating financial elements, such as reducing animal use or optimizing dose selection for safe-and-effective therapies. To make significant progress and accelerate the global effort to find effective and safe COVID-19 treatments, QSP could assist with drug choice, timing, and dosing as well as identifying drug combinations likely to provide added benefit. QSP and PBPK models, when validated with clinical data, allow simulations of changing inputs, which would let the clinician envision an optimized design of trials and fill the knowledge gap surrounding drug repositing in emergency settings. In the following, we will discuss modeling approaches applications leading to the repurposing of effective-and-safe drugs or drug combinations for COVID-19 treatment.
At a minimum, it is clear that SARS-CoV-2 infections in the lung cells can lead to severe respiratory failure and therefore pharmacological agents must provide sufficient levels in the lungs. However, clinical pharmacokinetic studies typically describe only plasma time-courses. In a general absence of distribution data in the lungs (e.g., HIV drugs), and in current settings where the experimental collection of drugs in the lungs will take time and it is hard to obtain, PBPK modeling, which can model the drug distribution in all the organs in the body, can provide in silico J o u r n a l P r e -p r o o f predictions of the drug concentration in the lungs. PBPK modeling will be an invaluable tool to predict likely antiviral effects of an experimental drug candidate for optimal strategies, ideal dosing, and timing for clinical evaluation, which can then be adjusted once lung tissue analysis in COVID-19 patients' data are available.
The repositioning of drugs intended for other diseases (drugs either already approved for use or terminated during preclinical and clinical testing) can have two main advantages. First, manufacturing should be already in place. Second, these compounds may have significant preclinical and clinical data about safety and efficacy as well as checked dosages and frequency.
This could be invaluable data to extrapolate safe regimens for treating COVID-19. The setback in drug repositioning, however, could be to elaborate a new dose or regimen that is effective in the COVID-19 target tissues. For instance, lopinavir-ritonavir is repositioned in COVID-19 adopting the HIV-prescribed regimen Kaletra (BID 400:100 mg), even though Kaletra may not target sufficiently the lungs against SARS-CoV-2. To investigate new targeting strategies in drug repositioning, PBPK modeling can represent a handy tool: we can compare in vitro 50% maximal SARS-CoV-2 inhibitory effect concentrations (EC 50 ), with both average range plasma concentrations (C max and C min ) and PBPK-based predicted concentrations of the drug candidate in the lungs (C max,lungs and C min,lungs ). In vivo efficacy of a repositioned drug can be further assessed by an Inhibitory Quotient (IQ 50 ), i.e., the ratio between minimal projected lung concentration C min,lungs, and EC 50 . IQ 50 should ideally be greater than unity when extrapolating in vitro to in vivo inhibitory effects for an antiviral 63 . For PBPK simulations, we took advantage of an online and validated platform brought by the CERTARA COVID-19 Modeling Consortium (CERTARA, NJ). They use PBPK and population PK approaches (popPBPK-PD models) 16 . Because antivirals may be easier to reposition and they can be promptly deployed to flat the viral load, we discuss in the next section modeling-based repositioning of J o u r n a l P r e -p r o o f antivirals (classified upon the mode of action), thus leaving immunomodulators or monoclonal antibodies repositioning for future work.
The presence of lopinavir in fluid and cells obtained from bronchoalveolar lavage of HIVinfected patients receiving lopinavir-ritonavir was demonstrated 64 , but it is unknown whether current HIV-based regimens are sufficiently tackling SARS-CoV-2. The EC 50 literature aggregated value against SARS-CoV-2 is 12 µg/ml for lopinavir. At the steady-state, Kaletra oral dosing reports plasma max-min concentrations in the EC 50 range (18-5.0 µg/ml, Table 2, Figure 4A ). When simulating the lungs, max-min lopinavir concentrations are higher than the plasma (28-9.0 µg/ml, Table 2 ). The Kaletra's Inhibition Quotient (IQ 50 = C min,lung / EC 50 ) is 0.75, which is lower than unity, and therefore Kaletra may be a moderate reposition, as its projection of in vivo efficacy might not be very promising. In the attempt to raise the plasma and lung concentrations of lopinavir (and IQ), we simulate a scenario where a loading dose of lopinavir (800:200 mg BID) is given, followed by Kaletra regimen. As a result, the drug increases in plasma as 23-6.0 µg/ml with an improved predicted lung concentration of 32-11 µg/ml, which yields a better IQ 50 = 0.92, and therefore this may be a more suitable regimen (Table 2 ). Nonetheless, it should be noted that lopinavir repositioning and modeling is hindered by several factors: (I) lopinavir-ritonavir generates variable pharmacokinetics probably due to circadian plasma clearance patterns and enzyme inductions 65, 66 . As the label and other clinical studies suggest, lopinavir is high in the first week of treatment and then it drops to a lower steady-state level (as observable in Figure 4A Table 2 ). Nonetheless, before concluding about an in vivo inefficient target pharmacokinetics of nelfinavir, we should wait for clinical results to corroborate the model predictions. In fact, in vivo hydroxylated nelfinavir M8 metabolite, which is not present in vitro, has activity against HIV and it may reach sufficiently high concentrations to add to the therapeutic effect. We should also be aware that the degree of accuracy in extrapolating EC 50 or IQ 50 from in vitro experiments to in vivo for protease inhibitors will be improved when protein-adjusted IQ 95 s become available 63 .
In conclusion, it is anticipated that lopinavir exposure in the lungs might approach in vitro 50% max effects on viral replication when given at an approved dose and frequency (with loading doses). In particular, the regimen made of 800:200 BID as a loading dose, followed by the standard 400:100 mg BID thereafter, may improve target IQ 50 and therefore could represent an optimal repositioning regimen to target SARS-CoV-2 protease activity in the early stages of infection (before the viral peak).
Anti-malarial chloroquine (CQ) is typically given in several COVID-19 trials as one loading dose of 1250 mg followed by 250 mg QD. As shown in Table 2 , CQ's EC 50 = 2.3 µg/ml is not achievable in plasma (1.1-0.08 µg/ml). According to modeling prediction, concentrations in the lungs are in the range of the EC 50 generating a good IQ value (7-5 µg/ml, IQ 50 = 2.3). Instead of raising the CQ dose, which could lead to prolonged QT intervals (thus exposing higher risks to patients with existing heart morbidity), the hydroxy derivative hydroxychloroquine (HCQ) has shown better pharmacokinetics as well as an improved EC 50 = 0.33 µg/ml 72 . HCQ is tested as a 400 mg loading dose, followed by a 200 mg QD. HCQ shows lower plasma levels than CQ (0.47-0.07 J o u r n a l P r e -p r o o f µg/ml), and although similar lung pharmacokinetics, much improved IQ 50 results (8-6 µg/ml, IQ 50 = 19, Table 2 ).
As anticipated, HCQ may have advantageous pharmacokinetics and improved predicted in vivo efficacy compared to CQ. Despite apparently high IQ 50 s, clinical results for CQ/HCQ seem to indicate a lack of clinical efficacy for either COVID-19 treatment or pre-exposure prophylaxis. It is unclear the reason for this, and interestingly, despite a high in vitro potency against the Ebola virus, CQ also failed to translate into its in vivo effectiveness in protecting animals from Ebola 63, 73 .
This could be that the reported EC 50 for HCQ might be highly dependent on the multiplicity of infection (MOI, the ratio between the number of viruses and the number of host cells), and when MOI is high enough, EC 50 = 5 µg/ml (EC 90 > 15 µg/ml) 74 , which would make an HCQ's IQ 90 to decrease much lower than 1, thus suggesting poor in vivo efficacy. Also, Fan et al. suggested that HCQ distribution in the whole blood hinders the real extracellular lung concentration, which is supposedly much lower than other authors believe 75 . Despite further investigation should shed light on this, if CQ/HCQ are still designed for COVID-19, perhaps in combination with other therapeutics, dose-ranging effects should be carefully considered due to prolonged residence in sensitive off-target tissues. Both compounds are characterized by very large volumes of distribution (500 L/kg) and very long half-lives as T 1/2,z = 50, 500 days in healthy volunteers for CQ and HCQ, respectively 76 , thus providing the rationale of important tissue distribution, including the heart (CQ's heart-to-plasma ratio in rodents is 17 77 ).
Remdesivir shows high potency against SARS-CoV-2 in vitro, with EC 50 documented as 0.52 µg/ml and EC 90 = 1.1 µg/ml 3, 78 . Remdesivir, lyophilized or in solution form, is approved as an injectable dosage formulation for infusion for COVID-19, i.e., 200 mg as a loading dose and 100 mg QD thereafter ( Figure 4B ). As shown in Table 2 Summarizing, with the limited preclinical and clinical data available, remdesivir active metabolites may achieve good intracellular concentrations in vivo in the lungs as demonstrated by a good IQ 50 viral inhibition level. Additionally, clinical and NHP evidence suggests an early commencement of the treatment (ideally before the viral peak) to obtain maximal antiviral efficacy. Note that while not generating particular adverse effects in healthy patients 79 , subjects with renal failure (eGFR < 30 mL/min), or on dialysis, or continuous Veno-Venous Hemofiltration, must not receive remdesivir, so other treatments should be recommended 3 .
The efficacy (or disease-modifying outcome or effect) of an antiviral pharmacological intervention depends on two main aspects: (I) the point of intervention in the viral lifecycle (see 
While lockdowns, quarantines, and general social distancing were recommended or mandated to control the SARS-CoV-2 pandemic and death count, they require compliance and discipline balancing between individual liberty and the sake of the public good. Ultimately, a vaccine capable of preventing infection or disease progression will be needed to fully return to normality in public gatherings and economic activities. Early sharing of the virus's genetic sequence along with transcriptomic mapping has enabled the accelerated design and testing of COVID-19 vaccines. Several recombinant viruses that express SARS-CoV-2 proteins or RNA formulations directed to express proteins are used in the US and Europe as vaccine candidates.
These vaccines do not contain viral proteins and RNA derived from the infectious virus, which is inactivated in the killed vaccine; thus, these vaccine candidates do not carry the risk of breakthrough vaccine-related SARS-CoV-2 infection. Due to the unprecedented research effort, and government investments in stockpiling promising candidates with large pharma partnerships, there are at least 6 vaccines leads, including mRNA-based, recombinant, and virus-like particles that are at the advanced Phase 2/3 testing stage 85 . Any of the vaccine candidates proven effective-and-safe in preventing infection or disease progression in at least 50% of individuals who are in high-risk groups, will be rapidly deployed. Albeit vaccines will overcome current social and economic restrictions and subsequent curtailing of COVID-19 spread, while vaccine dissemination will take some time, a highly active therapy is critical. We discuss next, the potential use of Systems Pharmacology when drug repositioning multiple drugs in terms of drug-drug interaction safety. It is followed by a discussion and modeling application in reformulating foregoing antivirals into long-acting therapies as an optimized COVID-19 treatment solution. The potential role of AI in the pandemic is also discussed.
As mentioned above, antiviral therapy may require the timely deployment of an antiviral 
Additionally, it is hypothesized that cytokine storms might alter CYP functions leading to unpredictable DDI metabolic reactions 86 .
In the case of HIV, potent drug combinations are devised to target multiple HIV proteins. In principle, it could the thought that a similar antiviral strategy is more effective to lower the SARS-CoV-2 load sooner. In the case of the initial design and evaluation of drug-combination candidates, the first step is to check (for each drug in combination) if any existing DDI has been discovered from labels or clinical studies, which can be a lengthy scrutinization. Consultable online tools are available such as www.covid19-druginteractions.org 87 and the University of Washington's DDI Database www.druginteractionsolutions.org 88 . Interestingly, when interrogating these resources, there is no apparent DDI sign for the combination lopinavir-ritonavir plus remdesivir.
In many cases, these DDI queries for the specific drug-combination in question can assist in quantifying the pharmacokinetic impact of DDI. Alternatively, more in-depth QSP approaches, especially PBPK, can be deployed to simulate the full pharmacokinetic profile of an expected change due to DDI. For example, PBPK can be used to identify the potential mechanisms underlying DDI: CYP, UGT, or transporter-mediated inhibition or induction are common instances of DDI. DDI for each drug-combination candidate may be reversible or irreversible, timedependent, or time-independent. Each of these categories has a subset of mechanisms. For example, enzyme inhibition can be competitive or uncompetitive. Knowing or predicting the type of inhibition and the pharmacodynamic effects in vivo will provide scientists with an invaluable safety check ahead of time. For these reasons, PBPK is the preferred dynamic framework to flag any risk associated with practicing a drug-combination therapy regimen with apparently safe drugs, especially if drug repositioning mandates dose adjusting.
The term long-acting (LA) has been employed in drug delivery to cover applications in oral and parenteral administrations where a drug was reformulated to extend the duration of pharmacokinetic exposure. Generally, LA medicines involve formulating drugs in polymeric or liposome nanocarriers to provide sustained drug-release at the site of injection to provide longacting plasma drug levels. The goal is to sustain target therapeutic concentration for periods ranging from weeks to months following a single administration. For instance, the two antiretrovirals cabotegravir and rilpivirine have been demonstrated non-inferior to the daily intake control for monthly pre-exposure and post-exposure prophylaxis (PEP) as a combination 89 . These HIV drugs are formulated independently using polymeric stabilizers in nanoparticulate formulations to provide sustained drug release from an intramuscular injection depot. Overall, long-acting injectable formulations of HIV medications hold the promise to maintain viral load suppression while reducing to a minimum the administrations.
In transforming small molecules intended for multiple daily intakes into a single-dose lasting 2-6 weeks, our laboratory has been developing drug-combination particles containing multiple (3 or 4) antiretrovirals for LA HIV therapy (DcNP platform technology). Using lipid excipients acting as a "glue", DcNP is shown to extend plasma drug concentration of the two to four drugs in formulation for 2 weeks or more in non-human primates (NHP) after a single injection. In addition, drugs given in DcNP can enhance mononuclear cellular drug uptake in the lymph nodes and the blood. Drugs delivered by DcNP are shown to be active, as the intracellular HIV drugs of nucleoside analogs, such as tenofovir and lamivudine, are able to convert into active metabolites (e.g., tenofovir diphosphate) with similar efficiency to that of controls with parent drugs without DcNP formulation. Antiretrovirals in DcNP have demonstrated good stability with particles thus protecting them from the native and rapid elimination, while reducing toxic accumulations, such as in the heart or kidney 90 . In vivo, DcNP transformed short-acting drugs that J o u r n a l P r e -p r o o f inhibit the HIV protease (lopinavir, ritonavir, atazanavir) and the reverse transcriptase (tenofovir, lamivudine), from half-lives of a few hours into weeks in both mononuclear cells and plasma [90] [91] [92] [93] .
Hence, DcNP is a subcutaneous delivery platform accommodating combinations of drugs with disparate physiochemical properties (e.g., water-solubility) suitable for transforming multiple daily intakes into a single-dose single-particle injection. This is why DcNP technology may hold potential for SARS-CoV-2 long-acting therapy, a concept that is not found in the literature at present. The proposal could exist for LA lopinavir-ritonavir, LA remdesivir, or the combination thereof.
To this end, we have herein studied whether DcNP technology could be utilized to transform COVID-19 drugs from short-acting into long-acting treatments. We use an exploratory QSP model simulation in our first attempt to envision the LA transformation. The 7-day target is chosen as LA duration because lopinavir and remdesivir, are given for a minimum of 7 or 5-days treatments in COVID-19 patients, respectively. For this QSP model simulation, we employed a validated mechanism-based pharmacokinetic (MBPK) model, which has been structured with data from NHP studies (IV and SC dosing) 90 . After empirically accounting for the metabolic differences between NHP and humans, we scaled the model to simulate the plasma concentration of LA lopinavir. According to the simulation, a single SC dose containing 800 mg LA lopinavir provided plasma drug levels greater or equal thane the EC 50 target ( Figure 4A ). If successfully developed as a LA lopinavir product, it could replace at least 7 days of Kaletra regimen (2-4 pills a day), while maintaining drug concentrations potentially effective against SARS-CoV-2 (lung concentrations are assumed higher than plasma based on Section V and not pursued here). Similarly, we simulated a remdesivir LA transformation too. First, we identified the free part of the MBPK model with the remdesivir clinical pharmacokinetic data 79 . In this case, we assumed that the DcNP, which has been shown to extend the pharmacokinetics of another antiviral nucleoside analogs, tenofovir and lamivudine 93 , can enable LA conversion of the short-acting remdesivir. With this assumption, we J o u r n a l P r e -p r o o f have simulated the time-course of DcNP-remdesivir and presented it in Figure 4B . As depicted in Figure 4B , one single 7 mg LA remdesivir dose could provide plasma drug concentrations above EC 50 levels for the entire duration of a 5-day treatment. This is a further example of how QSPbased outcomes can enable the potential development of new or improved pharmaceuticals.
Once successfully developed, an LA dosage form of anti-SARS-CoV-2 therapeutic could potentially provide sustained viral suppression and overcome current limitations on hospitals and care facilities in the COVID-19 pandemic. We believe that such long-acting therapeutic strategies would reduce the need for hospital stays, thus sparing resources and drugs while potentially lowering transmission rates.
Artificial intelligence (AI) is a set of automated computational methods to support data gathering, analysis, and subsequent decision making. These methods work well when Bigdata is available. In the context of research, in less than 8 months since the SARS-CoV-2 outbreak, a remarkably large number of reports (~2000/week) has formed big datasets 17 . AI may be used in drug discovery to screen leads for high affinity with SARS-CoV-2 targets. For example, the molecular design of a de novo molecule to potently bind with SARS-CoV-2 protease can be worked out via molecular docking and machine learning 94 . However, the AI-assisted compound will still necessitate long in vivo translation time. The AI role in later drug development, however, is yet to be determined.
Although AI for COVID-19 may be better used for data analysis (as performed in this paper to gather quantitative information), it could also find an appealing application as a diagnostic and prognostic tool. By training AI algorithms with validated lung CT or X-ray image data from COVID-19 positive patients, a computational tool can be designed to assist pathologists in forecasting the likelihood of COVID-19 paths towards severity 95, 96 . Another exciting approach uses machine J o u r n a l P r e -p r o o f learning to predict COVID-19 mortality in positive patients. By selecting the 3 most-discriminant blood biomarkers in hospitalized COVID-19 patients, namely, lactic dehydrogenase (an indicator of cell death), lymphocytes (inflammatory response), and high-sensitivity C-reactive proteins (an indicator of inflammation), the AI computer-based method predicts the mortality of individual patients more than 10 days in advance with more than 90% accuracy 97 . Having such an informative set of tools, albeit somewhat non-specific to viral infection, could reveal unique timedependent profiles of biomarker kinetics and dynamic profiles to assist physicians in quickly developing the most appropriate (personalized) pharmacological strategy.
Since its discovery in late 2019 as a novel pathogenetic coronavirus, the SARS-CoV-2 virus is far from being defeated. Owing to its high transmission rate, poorly recorded herd immunity, and an unclear possibility of re-infection, SARS-CoV-2 is projected to be eradicated in years. Therefore, effective pharmacological therapy is and will be the frontline to reduce infection rates and disease progression, especially for those who are exposed but not immune, regardless of the timing and availability of a vaccine. At early stages, effective antivirals are ideal for use in pre/post-exposure or at clinically mild symptom presentation. If antiviral therapy is insufficient or the disease has already progressed toward severity, immunomodulators should ameliorate the patient's over- 